Acceleron uncorks more mid-stage data for PAH drug sotatercept as part of the drug's resurrection campaign
Once on life support in pulmonary arterial hypertension, Acclereron’s sotatercept came back from the brink with winning data early last year. Now, with Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
